305 related articles for article (PubMed ID: 33579785)
1. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.
Iida K; Abdelhamid Ahmed AH; Nagatsuma AK; Shibutani T; Yasuda S; Kitamura M; Hattori C; Abe M; Hasegawa J; Iguchi T; Karibe T; Nakada T; Inaki K; Kamei R; Abe Y; Nomura T; Andersen JL; Santagata S; Hemming ML; George S; Doi T; Ochiai A; Demetri GD; Agatsuma T
Cancer Discov; 2021 Jun; 11(6):1508-1523. PubMed ID: 33579785
[TBL] [Abstract][Full Text] [Related]
2. A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.
George S; Heinrich MC; Somaiah N; Oppelt P; McLeod R; Nishioka S; Kundu MG; Qian X; Kumar P; Laadem A; Lau Y; Tran BP; Fallon M; Dosunmu O; Shi J; Naito Y
Clin Cancer Res; 2023 Sep; 29(18):3659-3667. PubMed ID: 37363962
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
6. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
9. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM
Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
12. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for the treatment of gastrointestinal stromal tumour.
Kasireddy V; von Mehren M
Expert Opin Emerg Drugs; 2017 Dec; 22(4):317-329. PubMed ID: 29183145
[TBL] [Abstract][Full Text] [Related]
14. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
15. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
[TBL] [Abstract][Full Text] [Related]
16. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.
Kim JO; Kim KH; Baek EJ; Park B; So MK; Ko BJ; Ko HJ; Park SG
Mol Oncol; 2022 Mar; 16(6):1290-1308. PubMed ID: 34407310
[TBL] [Abstract][Full Text] [Related]
18. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
19. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y
Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226
[TBL] [Abstract][Full Text] [Related]
20. [Medical treatment for gastrointestinal stromal tumor (GIST) in Japan].
Sato A; Hamada K; Imataka H
Gan To Kagaku Ryoho; 2012 May; 39(5):708-12. PubMed ID: 22584320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
